Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
JPRN |
Last refreshed on:
|
17 October 2023 |
Main ID: |
JPRN-UMIN000014888 |
Date of registration:
|
19/08/2014 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Everolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies
|
Scientific title:
|
Everolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies - Everolimus for vascular anomalies |
Date of first enrolment:
|
2014/06/01 |
Target sample size:
|
30 |
Recruitment status: |
Complete: follow-up complete |
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016463 |
Study type:
|
Interventional |
Study design:
|
Single arm Non-randomized
|
Phase:
|
Phase I
|
|
Countries of recruitment
|
Japan
| | | | | | | |
Contacts
|
Name:
|
Michio Ozeki |
Address:
|
Yanagito, Gifu-shi, Gifu
Japan |
Telephone:
|
058-230-6000 |
Email:
|
michioo@gifu-u.ac.jp |
Affiliation:
|
Gifu University Pediatrics |
|
Name:
|
Michio Ozeki |
Address:
|
Yanagito, Gifu-shi, Gifu
Japan |
Telephone:
|
058-230-6000 |
Email:
|
michioo@gifu-u.ac.jp |
Affiliation:
|
Gifu University Pediatrics |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: Allergy of everolimus
Age minimum:
Not applicable
Age maximum:
30years-old
Gender:
Male and Female
|
Health Condition(s) or Problem(s) studied
|
Lymphangiomatosis, Gorham-Stout disease and vascular anomalies
|
Intervention(s)
|
Oral everolimus
|
Primary Outcome(s)
|
Improvement of clinical symptoms at 1, 3, 6, 12 after administration
|
Source(s) of Monetary Support
|
Gifu university
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
Results
|
Results available:
|
Yes |
Date Posted:
|
|
Date Completed:
|
01/03/2015 |
URL:
|
|
|
|